2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch; Richard D Gelber; Martine J Piccart-Gebhart; Evandro de Azambuja; Marion Procter; Thomas M Suter; Christian Jackisch; David Cameron; Harald A Weber; Dominik Heinzmann; Lissandra Dal Lago; Eleanor McFadden; Mitch Dowsett; Michael Untch; Luca Gianni; Richard Bell; Claus-Henning Köhne; Anita Vindevoghel; Michael Andersson; A Murray Brunt; Douglas Otero-Reyes; Santai Song; Ian Smith; Brian Leyland-Jones; Jose Baselga; Herceptin Adjuvant (HERA) Trial Study Team

doi:10.1016/S0140-6736(13)61094-6

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch
, Richard D Gelber
, Martine J Piccart-Gebhart
, Evandro de Azambuja
, Marion Procter
, Thomas M Suter
, Christian Jackisch
, David Cameron
, Harald A Weber
, Dominik Heinzmann
, Lissandra Dal Lago
, Eleanor McFadden
, Mitch Dowsett
, Michael Untch
, Luca Gianni
, Richard Bell
, Claus-Henning Köhne
, Anita Vindevoghel
, Michael Andersson
, A Murray Brunt

Douglas Otero-Reyes, Santai Song, Ian Smith, Brian Leyland-Jones, Jose Baselga, Herceptin Adjuvant (HERA) Trial Study Team

468 Citationer (Scopus)

Abstract

Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	382
Udgave nummer	9897
Sider (fra-til)	1021-8
Antal sider	8
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(13)61094-6
Status	Udgivet - 21 sep. 2013

Adgang til dokumentet

10.1016/S0140-6736(13)61094-6

Citationsformater

Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., Dal Lago, L., McFadden, E., Dowsett, M., Untch, M., Gianni, L., Bell, R., Köhne, C.-H., Vindevoghel, A., Andersson, M., ... Herceptin Adjuvant (HERA) Trial Study Team (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), 1021-8. https://doi.org/10.1016/S0140-6736(13)61094-6

Goldhirsch, A, Gelber, RD, Piccart-Gebhart, MJ, de Azambuja, E, Procter, M, Suter, TM, Jackisch, C, Cameron, D, Weber, HA, Heinzmann, D, Dal Lago, L, McFadden, E, Dowsett, M, Untch, M, Gianni, L, Bell, R, Köhne, C-H, Vindevoghel, A, Andersson, M, Brunt, AM, Otero-Reyes, D, Song, S, Smith, I, Leyland-Jones, B, Baselga, J & Herceptin Adjuvant (HERA) Trial Study Team 2013, '2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial', Lancet, bind 382, nr. 9897, s. 1021-8. https://doi.org/10.1016/S0140-6736(13)61094-6

@article{28b45475948747ba8ee404942ac6677c,

title = "2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial",

abstract = "Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial.",

keywords = "Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Medication Adherence, Middle Aged, Receptor, erbB-2, Treatment Outcome",

author = "Aron Goldhirsch and Gelber, \{Richard D\} and Piccart-Gebhart, \{Martine J\} and \{de Azambuja\}, Evandro and Marion Procter and Suter, \{Thomas M\} and Christian Jackisch and David Cameron and Weber, \{Harald A\} and Dominik Heinzmann and \{Dal Lago\}, Lissandra and Eleanor McFadden and Mitch Dowsett and Michael Untch and Luca Gianni and Richard Bell and Claus-Henning K{\"o}hne and Anita Vindevoghel and Michael Andersson and Brunt, \{A Murray\} and Douglas Otero-Reyes and Santai Song and Ian Smith and Brian Leyland-Jones and Jose Baselga and \{Herceptin Adjuvant (HERA) Trial Study Team\}",

year = "2013",

month = sep,

day = "21",

doi = "10.1016/S0140-6736(13)61094-6",

language = "English",

volume = "382",

pages = "1021--8",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "9897",

}

TY - JOUR

T1 - 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA)

T2 - an open-label, randomised controlled trial

AU - Goldhirsch, Aron

AU - Gelber, Richard D

AU - Piccart-Gebhart, Martine J

AU - de Azambuja, Evandro

AU - Procter, Marion

AU - Suter, Thomas M

AU - Jackisch, Christian

AU - Cameron, David

AU - Weber, Harald A

AU - Heinzmann, Dominik

AU - Dal Lago, Lissandra

AU - McFadden, Eleanor

AU - Dowsett, Mitch

AU - Untch, Michael

AU - Gianni, Luca

AU - Bell, Richard

AU - Köhne, Claus-Henning

AU - Vindevoghel, Anita

AU - Andersson, Michael

AU - Brunt, A Murray

AU - Otero-Reyes, Douglas

AU - Song, Santai

AU - Smith, Ian

AU - Leyland-Jones, Brian

AU - Baselga, Jose

AU - Herceptin Adjuvant (HERA) Trial Study Team

PY - 2013/9/21

Y1 - 2013/9/21

N2 - Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial.

AB - Trastuzumab has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant trastuzumab, but the optimum duration of treatment is unknown. We compared 2 years of treatment with trastuzumab with 1 year of treatment, and updated the comparison of 1 year of trastuzumab versus observation at a median follow-up of 8 years, for patients enrolled in the HERceptin Adjuvant (HERA) trial.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Agents

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Disease-Free Survival

KW - Drug Administration Schedule

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Medication Adherence

KW - Middle Aged

KW - Receptor, erbB-2

KW - Treatment Outcome

U2 - 10.1016/S0140-6736(13)61094-6

DO - 10.1016/S0140-6736(13)61094-6

M3 - Journal article

C2 - 23871490

SN - 0140-6736

VL - 382

SP - 1021

EP - 1028

JO - Lancet

JF - Lancet

IS - 9897

ER -

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater